Meeting details menu

Meeting Authors
Meeting Abstracts
Keynote lectures
Oral communications
Poster presentations
Special symposia
Other

Acta Physiologica Congress

Back

Acta Physiologica 2010; Volume 198, Supplement 677
Joint Meeting of the Scandinavian and German Physiological Societies
3/27/2010-3/30/2010
Copenhagen, Denmark


EFFECTS OF THE RENIN ANTAGONIST ALISKIREN ON ISOLATED VASCULAR SMOOTH MUSCLE ACTIVITY
Abstract number: P-MON-35

TSCHERPEL1 C, HOPP1 HH, KISTERS1 K, NOACK1 T

Aliskiren (Novartis) is a new antihypertensive drug which acts by binding to the protease Renin and inhibits the conversion of Angitensinogen to Angiotensin I.. It is hoped to prevent the incomplete blockade of the Renin-Angotensin- Aldosterone system by AT1-antagonists (sartane- sensitive). Vascular smooth muscle strips were prepared for measurement of mechanical activity using organ bath techniques. Alisikiren was tested on spontaneous activity, high potassium activation (K+40mM) and Vasopressin (3 nM). Vasopressin activated A. iliaca, aorta from rat relaxed slightly on Aliskiren (10 – 50 mM). In portal vein tone slightly increased. Using high potassium activation, Aliskiren induced a further small increase of tone (1-10 mM) and an inhibition in iliac artery and aorta at higher concentrations used (30 – 50 mM). Integral of spontaneous activity of rat portal vein was increased by 30 % and the frequency was three- fold after Aliskiren treatment (1-50 mM). It is concluded, that Aliskiren exerts vasoactive affects on isolated vascular smooth muscle especially on the rhythmicity of spontaneous active tissues which might be important in the microcirculatory system, where vasomotion is an important feature.

To cite this abstract, please use the following information:
Acta Physiologica 2010; Volume 198, Supplement 677 :P-MON-35

Our site uses cookies to improve your experience.You can find out more about our use of cookies in our standard cookie policy, including instructions on how to reject and delete cookies if you wish to do so.

By continuing to browse this site you agree to us using cookies as described in our standard cookie policy .

CLOSE